PMC:7195088 / 29998-31117
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T31 | 163-167 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T32 | 942-944 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T33 | 958-966 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T23 | 163-167 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T155 | 80-88 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T156 | 168-174 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T157 | 272-280 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T158 | 572-580 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T159 | 775-783 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T160 | 1008-1016 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T164 | 95-100 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T165 | 163-167 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
| T166 | 163-167 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
| T167 | 287-292 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T168 | 790-795 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T169 | 847-848 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T170 | 881-882 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
| T171 | 1023-1028 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T399 | 16-34 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T400 | 95-100 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T401 | 215-233 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T402 | 287-292 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T403 | 405-410 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
| T404 | 411-421 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T405 | 427-445 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T406 | 451-461 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T407 | 466-477 | Chemical | denotes | thalidomide | http://purl.obolibrary.org/obo/CHEBI_9513 |
| T408 | 491-496 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
| T409 | 497-507 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T410 | 513-531 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T411 | 537-547 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T412 | 739-757 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T413 | 790-795 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T414 | 942-944 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T416 | 972-990 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T417 | 1023-1028 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T230 | 90-131 | Sentence | denotes | Open-label RCT (NCT04244591, recruiting). |
| T231 | 132-198 | Sentence | denotes | Primary endpoint: lower Murray lung injury score at days 7 and 14. |
| T232 | 199-281 | Sentence | denotes | • Comparison of methylprednisolone vs. standard of care in patients with COVID-19. |
| T233 | 282-323 | Sentence | denotes | Open-label RCT (NCT04273321, recruiting). |
| T234 | 324-380 | Sentence | denotes | Primary endpoint: treatment failure (follow-up 14 days). |
| T235 | 381-581 | Sentence | denotes | • Comparison of inhaled alpha interferon plus methylprednisolone plus umifenovir vs. thalidomide plus inhaled alpha interferon plus methylprednisolone plus umifenovir in patients with severe COVID-19. |
| T236 | 582-633 | Sentence | denotes | Double-blind RCT (NCT04273581, not yet recruiting). |
| T237 | 634-701 | Sentence | denotes | Primary endpoint: time to clinical improvement (follow-up 28 days). |
| T238 | 702-784 | Sentence | denotes | • Comparison of different dosages of methylprednisolone in patients with COVID-19. |
| T239 | 785-826 | Sentence | denotes | Open-label RCT (NCT04263402, recruiting). |
| T240 | 827-908 | Sentence | denotes | Primary endpoints: (a) disease readmission at day 7; (b) critical stage at day 7. |
| T241 | 909-1017 | Sentence | denotes | • Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. |
| T242 | 1018-1067 | Sentence | denotes | Open-label RCT (NCT04329650, not yet recruiting). |
| T243 | 1068-1119 | Sentence | denotes | Primary endpoint: ICU admission (follow-up 29 days) |